EPIX Investors Have Final Opportunity Approaching to Lead ESSA Pharma Inc. Securities Fraud Lawsuit with the Schall Law Firm

Core Viewpoint - A class action lawsuit has been filed against ESSA Pharma Inc. for allegedly making false and misleading statements regarding its drug masofaniten in combination with enzalutamide, which did not demonstrate the expected efficacy in treating prostate cancer [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of the Securities Exchange Act of 1934, specifically §§10(b) and 20(a), and Rule 10b-5 [1]. - Investors who purchased ESSA's securities between December 12, 2023, and October 31, 2024, are encouraged to participate in the class action [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against ESSA - The complaint alleges that ESSA misled investors by claiming that masofaniten combined with enzalutamide was effective, while evidence suggested it was less effective than enzalutamide alone [4]. - The misleading statements led to investor damages once the true efficacy of the drug was revealed [4].